STOCK TITAN

Phathom Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced that its management team will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 3:15 p.m. GMT (10:15 a.m. ET). The conference runs from November 17-19, 2020, where the team will also engage in one-on-one meetings. Interested parties can access the live webcast and recorded presentations via the Phathom website. The company specializes in developing treatments for gastrointestinal diseases, focusing on the novel potassium competitive acid blocker, vonoprazan.

Positive
  • None.
Negative
  • None.

FLORHAM PARK, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 3:15 p.m. GMT (10:15 a.m. ET).

Company management will also participate in one-on-one meetings during the virtual conference which runs from November 17-19, 2020.

To access the live webcast and archived recordings for each presentation, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations.  Recordings will be available for 60 days following the event.

About Phathom
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders.  Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders.  For more information about Phathom, visit the Company’s website at www.phathompharma.com or follow the Company on LinkedIn at www.linkedin.com/company/phathompharma.

CONTACTS

Media Contact:
Nick Benedetto
1-877-742-8466
media@phathompharma.com

Investor Contact:
Todd Branning
1-877-742-8466
ir@phathompharma.com


FAQ

What is the date and time of Phathom Pharmaceuticals' fireside chat at the Jefferies Conference?

Phathom Pharmaceuticals' fireside chat is scheduled for November 18, 2020, at 3:15 p.m. GMT (10:15 a.m. ET).

When is the Jefferies Virtual London Healthcare Conference taking place?

The Jefferies Virtual London Healthcare Conference runs from November 17-19, 2020.

Where can I access the recorded presentations from Phathom Pharmaceuticals?

Recorded presentations can be accessed on the Phathom Pharmaceuticals website under the News & Events section.

What is the focus of Phathom Pharmaceuticals?

Phathom Pharmaceuticals focuses on developing novel treatments for gastrointestinal diseases.

What drug is Phathom Pharmaceuticals developing for gastrointestinal disorders?

Phathom Pharmaceuticals is developing vonoprazan, a novel potassium competitive acid blocker.

Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

PHAT Rankings

PHAT Latest News

PHAT Stock Data

555.22M
51.10M
7.73%
109.32%
20.55%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
FLORHAM PARK